Annals of Diagnostic Pathology
Volume 12, Issue 2 , Pages 85-89 , April 2008

Immunohistochemical detection of the X-linked inhibitor of apoptosis protein (XIAP) in cervical squamous intraepithelial neoplasia and squamous carcinoma

  • David E. Burstein, MD

      Affiliations

    • Department of Pathology, Box 1194, Mount Sinai School of Medicine, New York, NY 10029, USA
    • Department of Oncologic Sciences, Mount Sinai School of Medicine, New York, NY 10029, USA
    • Corresponding Author InformationCorresponding author. Department of Pathology, Box 1194 Mount Sinai School of Medicine, New York, NY 10029, USA. Tel.: +1 212 241 0364; fax: +1 212 289 2899.
    • ,
  • Muhammad T. Idrees, MD

      Affiliations

    • Department of Pathology, Box 1194, Mount Sinai School of Medicine, New York, NY 10029, USA
    • ,
  • Gon Li, PhD

      Affiliations

    • Department of Oncologic Sciences, Mount Sinai School of Medicine, New York, NY 10029, USA
    • ,
  • Maoxin Wu, MD, PhD

      Affiliations

    • Department of Oncologic Sciences, Mount Sinai School of Medicine, New York, NY 10029, USA
    • ,
  • Tamara Kalir, MD, PhD

      Affiliations

    • Department of Oncologic Sciences, Mount Sinai School of Medicine, New York, NY 10029, USA

References 

  1. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell. 1994;78:539–542
  2. Schimmer AD, Dalili S, Batey RA, Riedl SJ. Targeting XIAP for the treatment of malignancy. Cell Death Differ. 2006;13:179–188
  3. Holcik M, Gibson H, Korneluk RG. XIAP: apoptotic brake and promising therapeutic target. Apoptosis. 2001;6:253–261
  4. Berezovskaya O, Schimmer AD, Glinskii AB, Pinilla C, Hoffman RM, Reed JC, et al. Increased expression of apoptosis inhibitor protein XIAP contributes to anoikis resistance of circulating human prostate cancer metastasis precursor cells. Cancer Res. 2005;65:2378–2386
  5. Holcik M, Yeh C, Korneluk RG, Chow T. Translational upregulation of X-linked inhibitor of apoptosis (XIAP) increases resistance to radiation induced cell death. Oncogene. 2000;19:4174–4177
  6. Tong QS, Zheng LD, Wang L, Zeng FQ, Chen FM, Dong JH, et al. Downregulation of XIAP expression induces apoptosis and enhances chemotherapeutic sensitivity in human gastric cancer cells. Cancer Gene Ther. 2005;12:509–514
  7. Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, Borden EC. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ. 2004;11:915–923
  8. Sasaki H, Sheng Y, Kotsuji F, Tsang BK. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res. 2000;60:5659–5666
  9. McManus DC, Lefebvre CA, Cherton-Horvat G, St-Jean M, Kandimalla ER, Agrawal S, et al. Loss of XIAP protein expression by RNAi and antisense approaches sensitizes cancer cells to functionally diverse chemotherapeutics. Oncogene. 2004;23:8105–8117
  10. Muris JJ, Cillessen SA, Vos W, van Houdt IS, Kummer JA, van Krieken J, et al. Immunohistochemical profiling of caspase signaling pathways predicts clinical response to chemotherapy in primary nodal diffuse large B-cell lymphomas. Blood. 2005;105:2916–2923
  11. Tamm I, Richter S, Scholz F, Schmelz K, Oltersdorf D, Karawajew L, et al. XIAP expression correlates with monocytic differentiation in adult de novo AML: impact on prognosis. J Hematol. 2004;5:489–495
  12. Tamm I, Richter S, Oltersdorf D, Creutzig U, Harbott J, Scholz F, et al. High expression levels of x-linked inhibitor of apoptosis protein and survivin correlate with poor overall survival in childhood de novo acute myeloid leukemia. Clin Cancer Res. 2004;10:3737–3744
  13. Ramp U, Krieg T, Caliskan E, Mahotka C, Ebert T, Willers R, et al. XIAP expression is an independent prognostic marker in clear-cell renal carcinomas. Hum Pathol. 2004;35:1022–1028
  14. Harlin H, Reffey SB, Duckett CS, Lindsten T, Thompson CB. Characterization of XIAP-deficient mice. Mol Cell Biol. 2001;21:3604–3608
  15. In:  Kurman RJ editors. Blaustein's pathology of the female genital tract. 5th ed.. New York: Springer; 2002;p. 280–281
  16. In:  Kurman RJ editors. Blaustein's pathology of the female genital tract. 5th ed.. New York: Springer; 2002;p. 339–340
  17. Kristensen GB, Abeler VM, Risberg B, Tropé C, Bryne M. Tumor size, depth of invasion, and grading of the invasive tumor front are the main prognostic factors in early squamous cell cervical carcinoma. Gynecol Oncol. 1999;74:245–251
  18. Jaffer S, Orta L, Sunkara L, Sabo E, Burstein DE. Immunohistochemical detection of anti-apoptotic protein XIAP in mammary carcinoma, Human Pathol 2007;38:864-70.
  19. Nagi C, Xiao G-Q, Li G, Genden E, Burstein DE. Immunohistochemical detection of XIAP in head and neck squamous cell carcinoma. Ann Diagn Pathol [in press].
  20. Idrees MT, Schlosshauer PW, Burstein DE. X-linked inhibitor of apoptosis expression in benign, hyperplastic and endometrial carcinoma (abstract). Arch Pathol Lab Med. 2006;130:238
  21. Liu SS, Tsang BK, Cheung AN, et al. Anti-apoptotic proteins, apoptotic and proliferative parameters and their prognostic significance in cervical carcinoma. Eur J Cancer. 2001;37(9):1104–1116
  22. Kamsteeg M, Rutherford T, Sapi E, Bozena Hanczaruk B, Shahabi S, Flick M, et al. Phenoxodiol—an isoflavone analog—induces apoptosis in chemoresistant ovarian cancer cells. Oncogene. 2003;22:2611–2620
  23. Rutherford TD, Makkenchery A, Mor G. Phenoxodiol phase Ib/II study in patients with recurrent ovarian cancer that are resistant to second line chemotherapy. J Soc Gynecol Invest. 2004;11:254
  24. Rosato RR, Dai Y, Almenara JA, Maggio SC, Grant S. Potent antileukemic interactions between flavopiridol and TRAIL/Apo2L involve flavopiridol-mediated XIAP downregulation. Leukemia. 2004;18(11):1780–1788
  25. Grant S, Dent P. Gene profiling and the cyclin-dependent kinase inhibitor flavopiridol: what's in a name?. Mol Cancer Ther. 2004;3:873–875
  26. Aguero MF, Facchinetti MM, Sheleg Z, Senderowicz AM. Phenoxodiol, a novel isoflavone, induces G1 arrest by specific loss in cyclin-dependent kinase 2 activity by p53-independent induction of p21WAF1/CIP1. Cancer Res. 2005;65:3364–3373

☆ Supported by a generous bequest from the Estate of Hilda Leveen.

PII: S1092-9134(07)00058-5

doi: 10.1016/j.anndiagpath.2007.04.008

Annals of Diagnostic Pathology
Volume 12, Issue 2 , Pages 85-89 , April 2008

Article Tools

* Image Usage & Resolution